Skip to main content
. 2022 Jun 28;14(13):3159. doi: 10.3390/cancers14133159

Figure 1.

Figure 1

Flow chart showing patients included in the study and the availability of NGS and RNAseq results. Patients are grouped by PFS: Early progressors (PFS < 6 months; N = 41), intermediate progressors (PFS 6–24 months for 0–1 line; 6–9 months for 2+ lines; N = 66), and late progressors (PFS > 24 months for 0–1 line; >9 months for 2+ lines; N = 37). Of 144 patients with NGS results, 29 patients underwent Tempus testing and had RNA seq data available (N = 24 patients with 0–1 line were used for differential gene expression).